Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Common Equity (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Common Equity data on record, last reported at $346.2 million in Q4 2025.

  • For Q4 2025, Common Equity rose 73.51% year-over-year to $346.2 million; the TTM value through Dec 2025 reached $346.2 million, up 73.51%, while the annual FY2025 figure was $346.2 million, 73.51% up from the prior year.
  • Common Equity reached $346.2 million in Q4 2025 per TNGX's latest filing, up from $160.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $365.4 million in Q3 2021 and bottomed at $54.9 million in Q2 2021.
  • Average Common Equity over 5 years is $234.2 million, with a median of $248.6 million recorded in 2022.
  • Peak YoY movement for Common Equity: soared 7208.25% in 2021, then plummeted 45.51% in 2025.
  • A 5-year view of Common Equity shows it stood at $344.7 million in 2021, then decreased by 27.64% to $249.5 million in 2022, then increased by 1.46% to $253.1 million in 2023, then dropped by 21.17% to $199.5 million in 2024, then surged by 73.51% to $346.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $346.2 million in Q4 2025, $160.0 million in Q3 2025, and $135.0 million in Q2 2025.